Evaxion Biotech A/S (EVAX)

Market Cap	15.85M
Revenue (ttm)	3.30M
Net Income (ttm)	-11.46M
Shares Out	6.27M
EPS (ttm)	-12.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,713
Open	2.690
Previous Close	2.660
Day's Range	2.510 - 2.690
52-Week Range	2.220 - 22.050
Beta	-0.27
Analysts	Strong Buy
Price Target	33.33 (+1,217.39%)
Earnings Date	Mar 26, 2025

About EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-cl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://www.evaxion-biotech.com

Analyst Forecast

According to 3 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $33.33, which is an increase of 1,217.39% from the latest price.

Price Target

$33.33

(1,217.39% upside)

Analyst Consensus: Strong Buy